ZETA and HOPE Announce First Patient Treatment with Zeta TMS Navigation System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 54 minutes ago
0mins
Source: PRnewswire
- FDA-Cleared Treatment System: ZETA SURGICAL and HOPE Therapeutics have announced the first patient treatment using the FDA-cleared Zeta TMS Navigation System at their Florida clinics, marking a significant advancement in psychiatric treatment that is expected to improve outcomes and enhance patients' quality of life.
- Precision Navigation Technology: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and repeatability in treatment delivery, thereby enhancing treatment efficacy.
- Multi-Site Implementation: HOPE Therapeutics has installed the Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, with patient treatments commencing this week, which is anticipated to expand access to personalized TMS therapy and address the needs of patients with treatment-resistant depression.
- Commitment from Industry Leaders: Raahil Sha, Co-Founder of ZETA, stated that the introduction of the Zeta TMS Navigation System will bring surgical-grade accuracy to TMS clinics, driving the ongoing evolution of psychiatric care and improving patient treatment experiences and outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRXP
Wall Street analysts forecast NRXP stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.900
Low
25.00
Averages
37.67
High
48.00
Current: 3.900
Low
25.00
Averages
37.67
High
48.00
About NRXP
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ZETA and HOPE Announce First Patient Treatment with TMS Navigation System
- First Patient Treatment: ZETA SURGICAL and HOPE Therapeutics successfully conducted the first patient treatment with the FDA-cleared Zeta TMS Navigation System at their Sarasota clinic, marking a significant milestone in precision treatment for depression.
- Technological Innovation: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and reliability in treatment delivery.
- Expanded Treatment Access: The system has been implemented at HOPE's clinics in West Palm Beach and Sarasota, expected to offer personalized TMS therapy to more patients with treatment-resistant depression, thereby enhancing patient quality of life.
- Industry Impact: Raahil Sha, Co-Founder of ZETA, stated that the application of this technology will transform psychiatric care by improving treatment accuracy and personalization, further expanding the clinical applications of TMS across the country.
See More
ZETA and HOPE Announce First Patient Treatment with Zeta TMS Navigation System
- FDA-Cleared Treatment System: ZETA SURGICAL and HOPE Therapeutics have announced the first patient treatment using the FDA-cleared Zeta TMS Navigation System at their Florida clinics, marking a significant advancement in psychiatric treatment that is expected to improve outcomes and enhance patients' quality of life.
- Precision Navigation Technology: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and repeatability in treatment delivery, thereby enhancing treatment efficacy.
- Multi-Site Implementation: HOPE Therapeutics has installed the Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, with patient treatments commencing this week, which is anticipated to expand access to personalized TMS therapy and address the needs of patients with treatment-resistant depression.
- Commitment from Industry Leaders: Raahil Sha, Co-Founder of ZETA, stated that the introduction of the Zeta TMS Navigation System will bring surgical-grade accuracy to TMS clinics, driving the ongoing evolution of psychiatric care and improving patient treatment experiences and outcomes.
See More
NRx Pharmaceuticals Receives FDA Approval for NRX-101 Use
- FDA Approval for Expanded Use: NRx Pharmaceuticals announced that the FDA has approved an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine and lurasidone aimed at augmenting accelerated Transcranial Magnetic Stimulation for depression treatment, marking a significant advancement in mental health care.
- Increased Patient Accessibility: While pivotal clinical trials continue, the company has decided to provide NRX-101 to doctors and eligible patients, ensuring that this potentially life-saving treatment is available as quickly as possible to meet the urgent needs of depression sufferers.
- New Study Initiation: NRx Pharmaceuticals has also launched the SPARC-TMS study, which aims to evaluate the efficacy of the NRX-101-TMS combination in treating patients with Treatment-Resistant Depression, further driving innovation in depression treatment.
- Transparent Cost Structure: Initially, patients will only need to cover shipping expenses and costs associated with FDA-required data collection, as the company will not charge for the investigational drug itself, thereby reducing the financial burden on patients and promoting broader access to the medication.
See More
NRx Pharmaceuticals Receives FDA Approval for NRX-101 Expanded Access
- FDA Approval for Expanded Use: NRx Pharmaceuticals' NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, has received FDA approval for use in accelerated Transcranial Magnetic Stimulation (TMS), aimed at aiding patients with Treatment-Resistant Depression and suicidality, marking a significant advancement in the mental health sector.
- Clinical Trial Initiation: The company has launched a pivotal clinical trial (SPARC-TMS study) to assess the efficacy of NRX-101 in augmenting TMS, expected to be conducted in both civilian and military treatment facilities, potentially providing new treatment options and enhancing the company's competitive position in the psychiatric drug market.
- Expanded Access Protocol: Through the FDA's Expanded Access Protocol, NRX-101 will be made available to patients unable to participate in clinical trials under compassionate care mechanisms, initially charging only for shipping and FDA-required data collection costs, demonstrating the company's strong commitment to patient needs.
- R&D Challenges and Solutions: NRx required two years of research and development to control impurities and achieve long-term stability for NRX-101, reflecting the company's technical capabilities in drug development and commitment to patient safety, especially in the challenging compounded drug market for DCS.
See More
NRx Pharmaceuticals Presents Efficacy of IV Ketamine for Depression Treatment
- Significant Findings: Among 8,224 patients treated with IV ketamine, 34% achieved remission compared to only 26% in the 1,830 patients treated with intranasal esketamine, indicating a clear efficacy advantage for IV ketamine.
- Clinical Data Support: The study revealed a response rate of 63% for IV ketamine patients versus 58% for those on intranasal esketamine, suggesting that IV ketamine may offer superior treatment responses in clinical settings, potentially influencing future treatment decisions.
- Policy Context Impact: This research underscores the importance of Real World Evidence (RWE) in drug approvals for depression, aligning with recent White House Executive Orders and Congressional appropriations language, which may facilitate market access for related medications.
- Future Outlook: NRx Pharmaceuticals' CEO expressed anticipation for results from larger confirmatory studies, which will provide stronger support for the clinical application of IV ketamine and further advance the company's strategic development in mental health.
See More
NRx Pharmaceuticals Closes $22.3 Million Public Offering
- Successful Offering: NRx Pharmaceuticals has successfully closed a public offering raising approximately $22.3 million at a price of $3.50 per share, reflecting market confidence in its future growth, with proceeds earmarked for operational support and expansion.
- Clear Use of Funds: The net proceeds from the offering will be utilized for working capital and general corporate purposes, aimed at advancing the company's research and development efforts in therapeutics for central nervous system disorders, particularly for suicidal depression.
- Leadership Remarks: CEO Jonathan Javitt expressed gratitude to investors for their trust and emphasized the company's commitment to developing lifesaving drugs, especially in light of the alarming statistic that an American dies by suicide every 11 minutes.
- Regulatory Compliance: The offering was conducted under an effective registration statement approved by the SEC on December 22, 2025, ensuring the company's compliance within legal frameworks, thereby enhancing investor confidence in its transparency and legitimacy.
See More
ZETA and HOPE Announce First Patient Treatment with TMS Navigation System
- First Patient Treatment: ZETA SURGICAL and HOPE Therapeutics successfully conducted the first patient treatment with the FDA-cleared Zeta TMS Navigation System at their Sarasota clinic, marking a significant milestone in precision treatment for depression.
- Technological Innovation: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and reliability in treatment delivery.
- Expanded Treatment Access: The system has been implemented at HOPE's clinics in West Palm Beach and Sarasota, expected to offer personalized TMS therapy to more patients with treatment-resistant depression, thereby enhancing patient quality of life.
- Industry Impact: Raahil Sha, Co-Founder of ZETA, stated that the application of this technology will transform psychiatric care by improving treatment accuracy and personalization, further expanding the clinical applications of TMS across the country.
See More
ZETA and HOPE Announce First Patient Treatment with Zeta TMS Navigation System
- FDA-Cleared Treatment System: ZETA SURGICAL and HOPE Therapeutics have announced the first patient treatment using the FDA-cleared Zeta TMS Navigation System at their Florida clinics, marking a significant advancement in psychiatric treatment that is expected to improve outcomes and enhance patients' quality of life.
- Precision Navigation Technology: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and repeatability in treatment delivery, thereby enhancing treatment efficacy.
- Multi-Site Implementation: HOPE Therapeutics has installed the Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, with patient treatments commencing this week, which is anticipated to expand access to personalized TMS therapy and address the needs of patients with treatment-resistant depression.
- Commitment from Industry Leaders: Raahil Sha, Co-Founder of ZETA, stated that the introduction of the Zeta TMS Navigation System will bring surgical-grade accuracy to TMS clinics, driving the ongoing evolution of psychiatric care and improving patient treatment experiences and outcomes.
See More
NRx Pharmaceuticals Receives FDA Approval for NRX-101 Use
- FDA Approval for Expanded Use: NRx Pharmaceuticals announced that the FDA has approved an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine and lurasidone aimed at augmenting accelerated Transcranial Magnetic Stimulation for depression treatment, marking a significant advancement in mental health care.
- Increased Patient Accessibility: While pivotal clinical trials continue, the company has decided to provide NRX-101 to doctors and eligible patients, ensuring that this potentially life-saving treatment is available as quickly as possible to meet the urgent needs of depression sufferers.
- New Study Initiation: NRx Pharmaceuticals has also launched the SPARC-TMS study, which aims to evaluate the efficacy of the NRX-101-TMS combination in treating patients with Treatment-Resistant Depression, further driving innovation in depression treatment.
- Transparent Cost Structure: Initially, patients will only need to cover shipping expenses and costs associated with FDA-required data collection, as the company will not charge for the investigational drug itself, thereby reducing the financial burden on patients and promoting broader access to the medication.
See More
NRx Pharmaceuticals Receives FDA Approval for NRX-101 Expanded Access
- FDA Approval for Expanded Use: NRx Pharmaceuticals' NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, has received FDA approval for use in accelerated Transcranial Magnetic Stimulation (TMS), aimed at aiding patients with Treatment-Resistant Depression and suicidality, marking a significant advancement in the mental health sector.
- Clinical Trial Initiation: The company has launched a pivotal clinical trial (SPARC-TMS study) to assess the efficacy of NRX-101 in augmenting TMS, expected to be conducted in both civilian and military treatment facilities, potentially providing new treatment options and enhancing the company's competitive position in the psychiatric drug market.
- Expanded Access Protocol: Through the FDA's Expanded Access Protocol, NRX-101 will be made available to patients unable to participate in clinical trials under compassionate care mechanisms, initially charging only for shipping and FDA-required data collection costs, demonstrating the company's strong commitment to patient needs.
- R&D Challenges and Solutions: NRx required two years of research and development to control impurities and achieve long-term stability for NRX-101, reflecting the company's technical capabilities in drug development and commitment to patient safety, especially in the challenging compounded drug market for DCS.
See More
NRx Pharmaceuticals Presents Efficacy of IV Ketamine for Depression Treatment
- Significant Findings: Among 8,224 patients treated with IV ketamine, 34% achieved remission compared to only 26% in the 1,830 patients treated with intranasal esketamine, indicating a clear efficacy advantage for IV ketamine.
- Clinical Data Support: The study revealed a response rate of 63% for IV ketamine patients versus 58% for those on intranasal esketamine, suggesting that IV ketamine may offer superior treatment responses in clinical settings, potentially influencing future treatment decisions.
- Policy Context Impact: This research underscores the importance of Real World Evidence (RWE) in drug approvals for depression, aligning with recent White House Executive Orders and Congressional appropriations language, which may facilitate market access for related medications.
- Future Outlook: NRx Pharmaceuticals' CEO expressed anticipation for results from larger confirmatory studies, which will provide stronger support for the clinical application of IV ketamine and further advance the company's strategic development in mental health.
See More
NRx Pharmaceuticals Closes $22.3 Million Public Offering
- Successful Offering: NRx Pharmaceuticals has successfully closed a public offering raising approximately $22.3 million at a price of $3.50 per share, reflecting market confidence in its future growth, with proceeds earmarked for operational support and expansion.
- Clear Use of Funds: The net proceeds from the offering will be utilized for working capital and general corporate purposes, aimed at advancing the company's research and development efforts in therapeutics for central nervous system disorders, particularly for suicidal depression.
- Leadership Remarks: CEO Jonathan Javitt expressed gratitude to investors for their trust and emphasized the company's commitment to developing lifesaving drugs, especially in light of the alarming statistic that an American dies by suicide every 11 minutes.
- Regulatory Compliance: The offering was conducted under an effective registration statement approved by the SEC on December 22, 2025, ensuring the company's compliance within legal frameworks, thereby enhancing investor confidence in its transparency and legitimacy.
See More
